Ether Compounds Targeting Factor D for Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by the complement pathway, such as age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, lack effective small molecule inhibitors for Factor D, leading to inadequate management of excessive activation and associated complications.
Innovation Solution
Development of ether compounds, as described in Formula I and their pharmaceutically acceptable salts, for use in treating disorders by modulating the complement pathway, specifically targeting Factor D to inhibit excessive activation and dampen detrimental complement activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for complement pathway disorders are used, then existing therapeutic options are available, but effective small molecule inhibitors for Factor D are lacking leading to inadequate management of excessive activation
Solution Approach 1:
The patent applies parameter changes by developing small molecule inhibitors with specific chemical structures (Formula I) that target Factor D. The compounds feature variable substituents (R1-R6, R12-R13) that can be modified to optimize binding affinity and selectivity for Factor D, transforming the therapeutic approach from antibody-based to small molecule-based inhibition of the complement pathway
Solution Approach 2:
The ether compounds act as intermediary molecules that bind to Factor D and prevent its interaction with other complement components. These small molecules serve as mediators between the therapeutic need (inhibiting complement activation) and the molecular target (Factor D), providing a bridge that enables selective inhibition without requiring large antibody molecules
2Object-affected harmful factors
If Factor D is inhibited to decrease complement pathway response, then excessive activation is reduced, but specific and effective small molecule inhibitors were previously unavailable
Solution Approach 1:
The patent segments the complement pathway into specific targetable components by focusing on Factor D as a discrete inhibition point. The small molecule inhibitors are designed to specifically bind to Factor D's active site or regulatory regions, allowing selective interruption of the alternative pathway without broadly suppressing all complement activities, thus managing excessive activation precisely
Solution Approach 2:
The invention changes the physical-chemical parameters of the inhibitor from large protein/antibody molecules to small synthetic molecules with defined molecular weights, solubility characteristics, and metabolic stability. This transformation enables oral administration potential, improved tissue penetration, and simplified manufacturing compared to biologic therapies
3Object-generated harmful factors
If ether compounds target Factor D to treat disorders, then inflammatory and immune responses are reduced, but the compounds must selectively inhibit complement pathway without affecting other physiological processes
Solution Approach 1:
The patent applies local quality by designing inhibitors that specifically target the Factor D active site or interface regions involved in complement component binding. The molecular structure (Formula I with specific substituent patterns) is optimized to interact with unique structural features of Factor D, ensuring that inhibition is localized to this specific protein-protein interaction without disrupting other physiological processes involving similar enzymes
Data Source
AI summary
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.